Tucaxen 150 MG Tablet ( Tucatinib)

Basic Product Information of Tucaxen (Tucatinib) 150mg

How Tucaxen (Tucatinib) Works

Tucaxen contains Tucatinib, a tyrosine kinase inhibitor that selectively targets HER2 (human epidermal growth factor receptor 2). In HER2-positive breast cancer, tumour cells overexpress HER2, driving continuous, abnormal growth and survival signalling. Tucatinib inhibits phosphorylation of both HER2 and its binding partner HER3, blocking the downstream MAPK and AKT signalling pathways that these receptors would otherwise activate to promote tumour cell proliferation.

In laboratory studies, the combination of Tucatinib and trastuzumab showed increased anti-tumour activity compared to either drug used alone, supporting the rationale for combining Tucaxen with trastuzumab (and capecitabine) in the approved regimen. Because Tucatinib has been shown to cross the blood-brain barrier in preclinical models, it has demonstrated meaningful activity in patients with HER2-positive breast cancer that has spread to the brain, a population with historically limited treatment options.

Tucaxen is taken as a twice-daily oral tablet, always in combination with trastuzumab and, for the breast cancer indication, capecitabine, as part of a physician-directed treatment regimen.

Indications for Tucaxen (Tucatinib)

Tucaxen (Tucatinib) is indicated for the following conditions:

Benefits of Tucaxen (Tucatinib) 150mg

How to Take Tucaxen (Tucatinib)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Tucaxen treatment. Your oncologist will check liver function tests before starting treatment, every 3 weeks during treatment, and as clinically indicated, given the risk of hepatotoxicity. Monitoring also includes close attention to bowel symptoms, as diarrhoea is common and can become severe without prompt management, along with periodic complete blood counts and monitoring in line with the trastuzumab and capecitabine components of the regimen. Report any yellowing of the skin or eyes, severe or persistent diarrhoea, unusual fatigue, abdominal pain, or signs of dehydration to your oncology team immediately.

Drug Interactions and Important Information

Avoid concomitant use of Tucaxen with strong CYP2C8 inhibitors (such as gemfibrozil); if unavoidable, a dose reduction is required as detailed in the dosing section above. Avoid concomitant use with strong CYP3A4 or moderate/strong CYP2C8 inducers, as these may significantly reduce Tucatinib exposure and effectiveness.

Tucatinib is itself a strong CYP2C8 inhibitor and a weak-to-moderate CYP3A4 inhibitor, meaning it can increase the plasma concentration of certain other medications, including some P-glycoprotein substrate drugs; your physician should review your full medication list carefully. Women of childbearing potential should use effective contraception during treatment and for a period after the final dose, and men should also use effective contraception during treatment and for a period afterwards. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Tucaxen.

Side Effects and Precautions

Who Should Use Tucaxen (Tucatinib)?

Tucaxen is suitable for adult patients with advanced, unresectable, or metastatic HER2-positive breast cancer, including those with brain metastases, who have received at least one prior anti-HER2-based treatment regimen in the metastatic setting, and are being treated with the full trastuzumab and capecitabine combination. It is prescribed by medical oncologists experienced in managing HER2-positive breast cancer. A thorough medical assessment including confirmed HER2-positive status, baseline liver function, and cardiac evaluation (given the trastuzumab component) is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Tucaxen under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Tucaxen is one of Everest’s specialty precision-oncology products, offering a bioequivalent alternative to Tukysa by Seagen/Pfizer at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Tucaxen (Tucatinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Tucaxen (Tucatinib) from Mediaid Pharmacy?

Tucaxen represents an important advance for patients with HER2-positive breast cancer, including those whose disease has spread to the brain. As the generic equivalent of Tukysa by Seagen/Pfizer, it delivers the same active ingredient, Tucatinib, with the same proven HER2-selective mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Tucaxen gives patients worldwide access to advanced targeted therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Tucatinib option with worldwide delivery, Tucaxen from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Tucaxen (Tucatinib)